drugset / Trial / NCT06081803
Evolocumab in STEMI
Phase 3
Active not recruiting
166 enrolled
Sejong General Hospital
Catholic University of Korea Eunpyeong St. Mary's Hospital · collabChonnam National University Hospital · collabDaegu Catholic University Medical Center · collabNational Health Insurance Service Ilsan Hospital · collabSamsung Medical Center · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The goal of this clinical trial is to compare the size of myocardial infarct between evolocumab and control groups in patients with ST segment elevation myocardial infarction who undergoing primary percutaneous coronary intervention(PCI). All study participants will undergo a cardiac MRI 4 weeks after primary reperfusion. The evolocumab group will receive 420 mg before PCI via subcutaneous injection.
Timeline
- Start
- 2020-12-05
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Evolocumab | Monoclonal antibody | 420 mg | Subcutaneous |